Victory Capital Management Inc. Has $7.88 Million Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Victory Capital Management Inc. trimmed its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 7.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 197,001 shares of the company’s stock after selling 15,685 shares during the quarter. Victory Capital Management Inc. owned about 0.40% of Amphastar Pharmaceuticals worth $7,880,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 2,815,596 shares of the company’s stock valued at $174,145,000 after acquiring an additional 48,203 shares during the last quarter. TD Asset Management Inc raised its holdings in Amphastar Pharmaceuticals by 67.4% in the 2nd quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock worth $67,663,000 after acquiring an additional 680,976 shares during the period. Epoch Investment Partners Inc. raised its holdings in Amphastar Pharmaceuticals by 34.8% in the 1st quarter. Epoch Investment Partners Inc. now owns 798,462 shares of the company’s stock worth $35,060,000 after acquiring an additional 205,932 shares during the period. Boone Capital Management LLC acquired a new position in Amphastar Pharmaceuticals during the 4th quarter worth $24,740,000. Finally, Bessemer Group Inc. grew its position in shares of Amphastar Pharmaceuticals by 21.5% in the first quarter. Bessemer Group Inc. now owns 395,941 shares of the company’s stock valued at $17,387,000 after purchasing an additional 69,968 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Piper Sandler reduced their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Finally, StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average price target of $63.00.

Insider Activity at Amphastar Pharmaceuticals

In other news, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the sale, the director now directly owns 75,409 shares in the company, valued at approximately $3,504,256.23. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the completion of the transaction, the director now owns 75,409 shares in the company, valued at approximately $3,504,256.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Rong Zhou sold 4,000 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the sale, the executive vice president now owns 118,388 shares in the company, valued at $5,724,059.80. The disclosure for this sale can be found here. Insiders have sold a total of 37,979 shares of company stock valued at $1,671,307 over the last quarter. 27.10% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH opened at $48.09 on Monday. The firm has a market capitalization of $2.34 billion, a PE ratio of 16.64, a PEG ratio of 0.85 and a beta of 0.82. The company has a current ratio of 3.52, a quick ratio of 2.63 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 1-year low of $36.56 and a 1-year high of $65.92. The business’s 50 day moving average is $43.44 and its 200-day moving average is $42.60.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. The firm had revenue of $182.39 million for the quarter, compared to analyst estimates of $171.29 million. Sell-side analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.